Selected Grants
Duke University Maternal-Fetal Medicine Units (MFMU) Network Clinical Center
ResearchCollaborating Investigator · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2023 - 2030CISA 2023 Clinical Contributing Task 1
ResearchCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028CISA 2023 Clinical Contributing Task 2
ResearchCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2027CISA 2024 RSV Infants Nirsevimab Study Task 1 - Lead
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2024 - 2027Najit SBIR - Chikingunya Phase 1 Vaccine Study
ResearchPrincipal Investigator · Awarded by Najit Technologies, Inc. · 2024 - 2027CIVICS Component C - Option 13A.2
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2026CIVICs Component C -Option 13 Equitable Adj #2
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2021 - 2026CISA 2023-03 Task 1 Lead - Enrollment/Follow up
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2026CIVICs C (75N93019C00054) Option 14
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2026CIVICs C Option 16 Equitable Adjustment
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2026CIVICS Component C - Option 9
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2026UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
Inst. Training Prgm or CMEMentor · Awarded by University of North Carolina - Chapel Hill · 2016 - 2026A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 months to < 24 mont
Clinical TrialPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2023 - 2026Duke-UNC Collaborative Pediatric Clinical Pharmacology Postdoctoral Training Program
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2021 - 2026Serum Obtained from Persons Convalescing from SARS-CoV-2 Infection for Purposes of Assay Validation
ResearchPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2025 - 2026Next Generation COVID-19 Vaccine Development Program
ResearchPrincipal Investigator · Awarded by Leidos Biomedical Research, Inc. · 2023 - 2025CIVICS Component C - Option 8 B.1
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2021 - 2025Lead Site Optional Task 1: Babies COVID-19 Vaccination
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2025A Phase 3, Randomized, Observer-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza in Healthy Individuals
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2023 - 2025CIVICS Component C - Option 5
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2025CIVICS Component A - Option 5
ResearchInvestigator · Awarded by National Institutes of Health · 2019 - 2025Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses - Option 1
ResearchInvestigator · Awarded by National Institutes of Health · 2022 - 2025ADEPT - An adaptive prenatal intervention to increase childhood vaccinations
ResearchCo Investigator · Awarded by Emory University · 2022 - 2025CIVICs Component C - Option 13A.1 Equitable Adjustment
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2025CIVICS Component C - Option 13A
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2025Immunogenicity and risk of autoimmune cross-reactivity of COVID-19 mRNA vaccines in SLE - RRF Investigator Award
ResearchMentor · Awarded by Rheumatology Research Foundation · 2022 - 2025Duke Women's Reproductive Health Research Scholars
Inst. Training Prgm or CMEMentor · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2020 - 2025A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Modified RNA Vaccines Against Influenza in Healthy Adults
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2024 - 2025VTEU Task Order 4 - Cost to Complete
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2025A Phase 2 Randomized, Open-Label, Multisite Trial to Inform Public Health Strategies Involving the Use of MVABN Vaccine for Mpox
Clinical TrialPrincipal Investigator · Awarded by Leidos Biomedical Research, Inc. · 2023 - 2025VTEU Task Area C Option 2 Equitable Adj
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2024 - 2024Lead Site Task 4: Simultaneous RZV and all V4 Vaccination (Lead) Mod 3
Clinical TrialCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2024CIVICS Component C - Option 8
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2024VTEU 13-0053 FY 2020 Option 1-Protocol Implementation
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2024CISA COVID Flu Immunogenicity
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2024CISA 10-Pediatric COVID-19 Vaccination (Lead)
ResearchCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2021 - 2024CISA 07 Adult RCT COVID-19 Vaccination (Lead)
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2020 - 20242020 CISA 04-COVID Maternal Study
ResearchCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2024MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BIVALENT BNT162b2 RNA-BASED VACCINE CANDIDATE IN HEALTHY CHILDREN
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2022 - 2024CIVICS Component C - Option 16
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2024COVID-19 Adaptive VAriant Immunologic Landscape Trial or COVAIL Trial
Clinical TrialPrincipal Investigator · Awarded by Leidos Biomedical Research, Inc. · 2022 - 2024VTEU 14-0053 Task C Option 2 Protocol Implementation
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2024VTEU: Task Area D: Research Laboratory Analysis Protocol #14-0053
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2015 - 2024Yellow Fever Vaccine Trial - U44 Clinical Trial with Najit
Clinical TrialCo-Principal Investigator · Awarded by Najit Technologies, Inc. · 2021 - 2024IMPAACT PTCL 17 Trial
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2018 - 2024Lead Site Task 5: Simultaneous RZV and all V4 Vaccination (Lead)
Clinical TrialCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2024Lead Site Task 6: Simultaneous RZV and all V4 Vaccination (Lead)
Clinical TrialCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2024EHR Surveillance of Lower Respiratory Tract (LRTI) and Respiratory Syncytial Virus (RSV) LRTI in Infants
ResearchPrincipal Investigator · Awarded by Clinetic, Inc · 2022 - 2024Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses - Option 4
ResearchInvestigator · Awarded by National Institutes of Health · 2023 - 2024A PHASE 1, OPEN-LABEL DOSE-FINDING AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN 5 TO 12 YEARS OF AGE
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2021 - 2024VTEU 14-0053 Task C Option 4 Protocol Implementation
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2023VTEU Task D Option 3 Protocol FY.2015.A4D14.0033
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2023VTEU 14-0053 Task C Option 3 Protocol Implementation
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2023VTEU Task Order 22 16-0058 - Cost to Complete
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2021 - 2023HVTN 3002 Protocol Funding (PF) - Durham Protocol-Specific Site
ResearchPrincipal Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2023CISA Consult 2022 Contributing Task 3
Clinical TrialInvestigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2023CISA Consult 2022 Contributing Task 1
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2023VTEU Sample Task Orders
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2013 - 2023Vaccine and Treatment Evaluation Units (VTEU)
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2013 - 2023VTEU TO #132 Base - Task Area A - FY.2020.A1B1C1D1.0123 - Option 2.A
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2021 - 2023A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER BLIND, DOSE-FINDING STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND POTENTIAL EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINS
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2020 - 2023A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2021 - 2023VTEU 18-0010.B1C1.0120_Task C Option 1
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2022VACCINE AND TREATMENT EVALUATION UNITS (VTEU) PROTOCOL DEVELOPMENT, IMPLEMENTATION AND ASSAYS TASK AREA B-D PHASE 1 PK TRIAL TO EVALUATE FOSFOMYCIN TASK ORDER 16-0058.B1C1D1.0076
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2022Task Area B-D Task Order 16-0058.B1C1D1.0076
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2022VTEU Task Order 16-0058.B1C1D1.0076 - Task D
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2022VTEU Task D Option 4 Protocol FY.2015.A4D14.0033
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2022VTEU Task D Option 1 Protocol FY.2015.A4D14.0033
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2022VTEU Task D Option 2 Protocol FY.2015.A4D14.0033
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2022CISA RFTP Syncope Prevention Study (Lead) 2020-2022
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2022CISA 2021-2022 - Clinical Consult - Opt 2
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2022CISA 2021-2022 - Clinical Consult - Base
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2022Clinical Vaccine Safety Evaluation - Contributing Site - Task COVID - Optional Task 3
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2022CISA 2018-2019 - Clinical Consult - Base
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2017 - 2022CISA 2018-2019 - Clinical Consult - Opt 2
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2017 - 2022CISA 2017 06 - Clinical Consult - Base
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2017 - 2022CISA 2017 06 - Clinical Consult - Opt 2
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2017 - 2022CISA Lead Site Task 3: Simultaneous RVZ and all V4 Vaccination (Lead)
Clinical TrialCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2021 - 2022RTOP 2018 CISA 01 Flublok Lead Task 3
ResearchCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2022RTOP 2018 CISA 01 Flublok Lead Task 2
ResearchCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2022RTOP 2018 CISA 01 Flublok Lead Task 4
ResearchCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2022CISA RTOP 2017-01 Apnea (Lead) - Option 2
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2019 - 2022RTOP 2018 CISA 01 Flublok Lead Task 1
ResearchCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2018 - 2022RTOP 2018 CISA 01 Flublok Lead Base
ResearchCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2018 - 2022"An adaptive prenatal (ADEPT) intervention to encourage childhood vaccinations
ResearchCo Investigator · Awarded by Centers for Disease Control and Prevention · 2021 - 2022Reducing disparities in adolescent HPV vaccination coverage in the Carolinas
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2018 - 2022CISA Shingrix 2020 Lead Site Task 2
Clinical TrialCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2022Lead Site Task 1: Simultaneous RZV and all V4 Vaccination (Lead)
Clinical TrialCo-Principal Investigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2021Adaptive COVID-19 Treatment Trial (ACTT)
ResearchInvestigator · Awarded by Leidos Biomedical Research, Inc. · 2020 - 2021RFTP 2018 CISA 05 FLUAD Logical Follow On Task 1
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2018 - 2021VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Option 1
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2021VTEU Protocol Implementation Option 1
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2021VTEU RTOP FY.2017.B8C12.0080 - Task B
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2021VTEU Task C Option 2 Protocol 14-0079.B1C1.0028
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2021CISA RTOP 2017-01 Apnea (Lead) - Option 1
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2017 - 2021IMPAACT 2021 Core funding PTCL 11
ResearchPrincipal Investigator · Awarded by Johns Hopkins University · 2019 - 2020CISA: 2015 CISA 02 - Contributing Site Base Task: Consultation for the LAIV and Asthma Study (Contributing)
Clinical TrialPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2015 - 2020CISA: 2015 CISA 02 - Contributing Site Optional Task 1: Enrollment and Data Collection for the LAIV and Asthma Study (Contributing)
Clinical TrialPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2015 - 2020CISA 2018-2019 - Clinical Consult - Opt 2
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2019 - 2020VTEU Task D Protocol FY.2015.D1B1C1.0032
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2020VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Base-A
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2020VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Base
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2020VTEU RTOP FY.2017.B8C12.0080 - Task C - Option 1
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2020VTEU RTOP FY.2017.B8C12.0080 - Task C - Option 8
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2020VTEU RTOP FY.2017.B8C12.0080 - Task C - Option 3
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2020VTEU Task Area D Option 9 Protocol FY.2016.D1.0026
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2020VTEU Task Area C Option 3 Protocol FY.2016.C1.0026
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2016 - 2020VAC057: Assess the reactogenicity, safety, and immunogenicity of a live attenuated universal influenza vaccine
Clinical TrialCo Investigator · Awarded by PATH · 2017 - 2020IMPAACT Trial--13 CF
ResearchPrincipal Investigator · Awarded by Johns Hopkins University · 2018 - 2019CISA RFTP 2017-03 Syncope Prevention Study (Lead) - Option 2
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2018 - 2019RFTP 2016 CISA 01 - Base - FLUAD vs. Fluzone® High-Dose Study (Lead)
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2016 - 2019VTEU 18-0010.B1C1.0120_Task B Base
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2019VTEU 14-0053 Task Area A Project Logistics and Site Activation
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2019VTEU: Task Area C: Protocol Implementation - Option 2 Protocol #14-0053
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2015 - 2019VTEU Task Order 18-0011.B1.C1.0116-Task B Base
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2019VTEU RTOP FY.2019.A1B1C1D1.0103 - Task A - Base
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2019VTEU Task C Option 1 Protocol 15-0066.B1C1D1.0041
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2016 - 2019VTEU Task Area D Option 8B Protocol FY.2016.D1.0026
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2016 - 2019VTEU Task B Base Protocol 15-0066.B1C1D1.0041
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2016 - 2018IMPAACT trial
ResearchPrincipal Investigator · Awarded by Johns Hopkins University · 2018 - 2018VTEU Task Area D Option 8 Protocol FY.2016.D1.0026
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2016 - 2018CISA RFTP 2017-03 Syncope Prevention Study (Lead) - Option 1
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2017 - 2018CISA RFTP 2017-03 Syncope Prevention Study (Lead) - Base
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2017 - 2018CISA: 2015 CISA 03 - Lead Site Optional Task 1 (Combined Options 1-11): Additional Subjects for Maternal Tdap and IIV Study (Lead)
Clinical TrialCo Investigator · Awarded by Centers for Disease Control and Prevention · 2016 - 2018CISA: 2015 CISA 03 - Lead Site Base Task: Maternal Tdap and IIV Study (Lead)
Clinical TrialCo Investigator · Awarded by Centers for Disease Control and Prevention · 2015 - 2018CISA RTOP 2017-01 Apnea (Lead) - Base
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2017 - 2018RFTP 2016 CISA 03 - Option 1 - Fever after Simultaneous Vaccination (Lead)
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2017 - 2018VTEU Task Area C Option 3B Protocol FY.2016.C1.0026
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2016 - 2018VTEU FY.2018.A1B1C1D1.0077 - Task A - Option 1
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2018VTEU FY.2018.A1B1C1D1.0077 Task Area A - Base
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2018VTEU Task B Option 2 - FY.2017.A1B1C1D1.0048
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2018VTEU Task C Option 1 Protocol 14-0079.B1C1.0028
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2016 - 2018VTEU Task Order 16-0047 -Task C Option 1
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2018VTEU Task Order 16-0047.C1.0090
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2018A Double-Blind, Randomized, Placebo-controlled, Phase 1 Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine, HydroVax-001, in Healthy Adults
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2018VTEU: Base -Task Area A: Project Logistics and Site Activation Protocol #14-0053
Clinical TrialCo-Principal Investigator · Awarded by National Institutes of Health · 2015 - 2017RFTP 2016 CISA 03 - Base - Fever after simultaneous vaccination (Lead)
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2016 - 2017VTEU Task Area B Option 2 Protocol FY.2016.B1.0026
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2016 - 2017CISA Clinical Consult TO I - Option 4
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2016 - 2017CISA Task Order No. 3 Tdap Safety in Pregnant Women Infant Option Task 1-CLIN0002
ResearchCo Investigator · Awarded by Centers for Disease Control and Prevention · 2014 - 2017VTEU Task A Option 1 - FY.2017.A1B1C1D1.0048
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2017VTEU Task A Base - FY.2017.A1B1C1D1.0048
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2016 - 2017CISA Task Order No. 3 Tdap Safety in Pregnant Women Infant Option Task 2-CLIN0003
ResearchCo Investigator · Awarded by Centers for Disease Control and Prevention · 2014 - 2017VTEU Task Area B Option 2 Protocol FY.2016.B1.0026
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2016 - 2017VTEU Task B Base Protocol 14-0079.B1C1.0028
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2016Option Three (3) of Contract No. 200-2012-53663, Task Order 0001
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2015 - 2016CISA TO2 Prophylactic Antipyretics Revision 1-A
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2014 - 2016CISA TO2 Prophylactic Antipyretics Revision 3-A
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2014 - 2016CISA Task Order No. 3 Tdap Safety in Pregnant Women
ResearchCo Investigator · Awarded by Centers for Disease Control and Prevention · 2013 - 2016VTEU Task A Protocol FY.2015.A4D14.0033
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2016Subcontract: Comparing Traditional and Participatory Dissemination of a Shared Decision Making Intervention
Clinical TrialPrincipal Investigator · Awarded by Carolinas HealthCare System · 2013 - 2016CISA TO2 Prophylactic Antipyretics
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2013 - 2016VTEU Task Area A, Base Protocol FY.2016.A1.0026
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2016VTEU: Option 1-Task Area B: Protocol Development Protocol #14-0053
Clinical TrialCo-Principal Investigator · Awarded by National Institutes of Health · 2015 - 2016Phase I CTU Task Area A: Administrative and Overal Clinical Operations Support and Concept Development
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2014 - 2015Multiscale Systems Immunology
ResearchInvestigator · Awarded by National Institutes of Health · 2010 - 2015VTEU Task Area A - FY.2015.A1.0016 Base
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2015Clinical Trial Services Agreement with bioCSL to Study the Performance of CSL Trivalent Influenza Vaccine
Clinical TrialPrincipal Investigator · Awarded by ACCELOVANCE, INC. · 2014 - 2015VTEU 12-0016: Task Area C: Protocol implementation
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2015VTEU 13-0053 Task Area B: Phase I, single dose, open-label, parallel group study comparing the pharmacokinetics and safety of PA-824 in subjects with mild, moderate, and severe hepatic impairment to matched, normal, healthy subjects.
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2015CISA-Task Order 1: Option 1
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2013 - 2014CISA
Clinical TrialPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2012 - 2013SAFETY AND IMMUNOGENICITY OF TDAP VACCINE IN HEALTHY PREGNANT WOMEN, SAFETY IN THEIR NEONATES, AND EFFECT OF MATERNAL IMMUNIZATION ON INFANT IMMUNE RESPONSES TO DTAP VACCINE - DMID 05-0048
ResearchCo-Principal Investigator · Awarded by University of Maryland · 2010 - 2012Effectiveness of a Vaccination Program in the Community ObGyn Setting
ResearchCo Investigator · Awarded by Centers for Disease Control and Prevention · 2008 - 2011A randomized double-blind trial on the safety and immunogenicity of inactivated trivalent influenza vaccine in pregnant women.
ResearchCo Investigator · Awarded by University of Maryland · 2009 - 2010Prevention of Influenza in Infants by Immunization of Their Contacts in the Household (PIIITCH study)
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2006 - 2009Preschool Vision Screening in Primary Care Settings
ResearchMentor · Awarded by National Institutes of Health · 2003 - 2008Implementing Research Findings for Practice Improvement
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2002 - 2006Epidemiologic Research Studies of AIDS and HIV Infection
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1998 - 2000Epidemiologic Research Studies Of Aids And Hiv Infection
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1995 - 1998Evaluation Of Perinatal Hiv Prevention In North Carolina
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1995 - 1998External Relationships
- Clinical Infectious Diseases
- Pfizer Inc.
- Shionogi, Inc.
- Vaxcyte
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.